Compounds for Lysosomal Modulation and Methods of Use
申请人:Bahr Ben A.
公开号:US20090281178A1
公开(公告)日:2009-11-12
Compounds useful for promoting lysosomal processes and thereby ameliorating the disruption of cellular and functional integrity induced by Aβ and other protein and glycoconjugate species are provided. Methods for the treatment of neurodegenerative diseases that involve protein accumulation and aggregation in the brain, such as Alzheimer's, Parkinson's and Huntington's Disease, are also provided.
Compounds for lysosomal modulation and methods of use
申请人:University of Connecticut
公开号:US08163953B2
公开(公告)日:2012-04-24
Compounds useful for promoting lysosomal processes and thereby ameliorating the disruption of cellular and functional integrity induced by Aβ and other protein and glycoconjugate species are provided. Methods for the treatment of neurodegenerative diseases that involve protein accumulation and aggregation in the brain, such as Alzheimer's, Parkinson's and Huntington's Disease, are also provided.
[EN] MATERIALS FOR CATHEPSIN B ENHANCEMENT AND METHODS OF USE<br/>[FR] SUBSTANCES POUR L'AMÉLIORATION DE LA CATHÉPSINE B ET MÉTHODES D'UTILISATION
申请人:THE UNIV OF NORTH CAROLINA AT PEMBROKE
公开号:WO2017096049A1
公开(公告)日:2017-06-08
The present invention provides methods for treating a subject afflicted with a protein accumulation disease or TBI, comprising administering to the subject at least one compound that increases the level of active cathepsin B in cells of the subject, or a pharmaceutically acceptable salt or ester thereof, in an amount that is effective to treat the subject. The present invention also provides compositions for treating a subject afflicted with a protein accumulation disease or TBI.
[EN] COMPOUNDS FOR LYSOSOMAL MODULATION AND METHODS OF USE<br/>[FR] COMPOSÉS POUR MODULATION LYSOSOMALE ET PROCÉDÉS D'UTILISATION
申请人:UNIV CONNECTICUT
公开号:WO2009129532A1
公开(公告)日:2009-10-22
Compounds useful for promoting lysosomal processes and thereby ameliorating the disruption of cellular and functional integrity induced by Aβ and other protein and glycoconjugate species are provided. Methods for the treatment of neurodegenerative diseases that involve protein accumulation and aggregation in the brain, such as Alzheimer's, Parkinson's and Huntington's Disease, are also provided.